Latest Breaking News On - Noam solomon - Page 7 : comparemela.com
The 50 Most Promising Israeli Startups - 2021
calcalistech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from calcalistech.com Daily Mail and Mail on Sunday newspapers.
ציונים תמותו : אישום בגין תקיפת האמבולנס ליד מאה שערים בפורים
ynet.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ynet.co.il Daily Mail and Mail on Sunday newspapers.
AlleyWatch
The immune system at its core is a complex system of cells, organs, and tissues. These components work in unison to fight infection in the form of microbes. Developing an understanding of how this intricate system works is critical in ensuring that society as a whole has adequate immune health to combat disease and infection.
Immunai has built the largest database for immunology in the world using machine learning and AI to map the entire immune system at a granular and specific level. This data can be leveraged by the healthcare industry to provide better therapeutics that get to market faster. This understanding will also allow biotech companies and pharmaceutical manufacturers to radically personalize therapeutics in the future. Immunai is initially focused on the oncology market but the offering is versatile can be applied to things like autoimmune disorders and infectious diseases like COVID-19.
אנחנו מגלחים 10 שנים ומיליארד וחצי דולר מתהליך פיתוח תרופה חדשה
themarker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarker.com Daily Mail and Mail on Sunday newspapers.
Immunai Joins 10x To Scale Single Cell Genomics December 21, 2020
By Allison Proffitt
December 21, 2020 | Immunai has announced its collaboration with 10x Genomics as one of the first 10x Certified Service Providers. Immunai will leverage 10x’s robust single-cell technologies to map hundreds of cell types and states. By applying its proprietary artificial intelligence and machine learning algorithms, Immunai supports biomarker discovery and insight generation to ultimately power new therapeutic discoveries and accelerate drug development.
Immunai was started by Luis Voloch and Noam Solomon about two years, Voloch told
Bio-IT World. The goal is to “revolutionize immunology” by scaling single cell genomics, he said, both in the lab and computationally.